Tenaya and Alnylam Partner in $1.13 Billion Cardiovascular Research Deal

Key Facts

1Tenaya Therapeutics entered a research collaboration with Alnylam Pharmaceuticals to discover novel genetic targets for cardiovascular diseases.

2Tenaya will receive up to $10 million in upfront payments, plus research funding and milestone payments of up to $1.13 billion.

3The collaboration combines Tenaya's expertise in heart disease target validation with Alnylam's RNAi therapeutic capabilities.

Tenaya Therapeutics and Alnylam Pharmaceuticals have announced a strategic research collaboration aimed at discovering novel genetic targets for cardiovascular diseases. Under the agreement, Tenaya will receive up to $10 million in upfront payments, along with research funding and potential milestone payments totaling $1.13 billion. The partnership leverages Tenaya's specialized expertise in heart disease target validation and Alnylam's industry-leading RNAi therapeutic platform. This collaboration focuses on developing disease-modifying treatments to address the underlying causes of various heart conditions. For Tenaya, the deal provides a significant capital infusion and long-term financial upside relative to its current market valuation. Meanwhile, Alnylam expands its therapeutic reach into the high-impact cardiovascular sector through this joint effort.